The effect of Sancai powder on glycemic variability of type 2 diabetes in the elderly: A randomized controlled trial. Issue 31 (31st July 2020)

• Record Type: Journal Article
• Authors: Zhou, Dongqi; Zhang, Li; Han, Xuke; Gao, Yang; Zeng, Min; Yu, Weiwei; Sun, Lisha; Chen, Qiu
• Is Part Of: Medicine. Volume 99:Issue 31(2020)
• Publication Date: 2020-07-31
• Subjects: elderly patients -- randomized controlled trial -- Sancai powder -- type 2 diabetes mellitus; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000020750
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Type 2 diabetes is a kind of metabolic disease. Its clinical characteristic is hyperglycemia. Recently, more and more elderly people suffer from type 2 diabetes, and the glycemic variability of the elderly is greater. In addition, blood sugar variation is more likely to cause diabetes complications than simple hyperglycemia. Sancai podwer (SC) is based on the theory of traditional Chinese medicine and gradually formed in the summary of clinical experience. It has the effect of lowering blood sugar and alleviating clinical symptoms of diabetes. But the existing evidence of its efficacy on glycemic variability is insufficient. So, in our study, the randomized controlled trials will be used as a research method to explore the effects of SC on glycemic variability of type 2 diabetes. Method: We will use randomized controlled experiments based on the recommended diagnostic criteria, inclusion and exclusion criteria. A total of 60 elderly patients with type 2 diabetes will be randomly divided into treatment group and control group, 30 cases in each group. The control group will receive conventional western medicine and the intervention group will receive SC combined with western medicine. The standard deviation and coefficient of variation of blood glucose level will be used as evaluation indexes. Discussion: This study can provide evidence for the clinical efficacy and safety of SC in elderly patients with type 2 diabetes mellitus. Trial registration: This study is registered on the Chinese Clinical Trial Registry: ChiCTR2000032611.